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when treated with vancomycin compared with infections
caused by more susceptible MRSA. Aggressive vancomycin
dosing to achieve trough concentrations 15 to 20 $g/ml has
been used to improve outcome when treating infections
caused by MRSA. The clinical utility of this strategy has not
been established; however, aggressive dosing is associated
with nephrotoxicity especially in patients weighing > 101 kg,
with reduced renal function and in intensive care settings.
Using vancomycin in combination with other antimicrobials
has not proven more effective either.
Treatment with other antimicrobials to which MRSA are
susceptible is increasingly used to address concerns regard-
ing the inefﬁcacy of vancomycin therapy for severe MRSA
infections. Clinical trials suggest that linezolid is at least
comparable to vancomycin for treatment of MRSA pneumo-
nia and for pharmacokinetic-pharmacodynamic reasons may
be preferable in selected patients. Daptomycin (6mg/kg/d)
was non-inferior to comparator regimens (low-dose gentam-
icin plus nafcillin or vancomycin) in a clinical trial treating
S. aureus bacteremia and right sided endocarditis; cure
rates were higher with daptomycin compared to vancomycin
(not statistically signiﬁcant) in trial patients with MRSA
bacteremia. Doses of daptomycin (10mg/kg/d) higher than
approved by the FDA are preferred by some experts when
treating MRSA bacteremia or endocarditis. Linezolid has
appeared effective in selected patients with persistent MRSA
bacteremia. Televancin, with dual mechanisms of cidality
versus MRSA, has recently been approved by the FDA for
treatment of complicated skin/soft tissue infection due to
MRSA and may offer additional options for treating severe
infections. New cephalosporins that bind to PBP2’ and to
which MRSA are susceptible are under development and
fusidic acid is attracting increasing interest as an agent for
combination therapy against severe MRSA infections.
doi:10.1016/j.ijid.2010.02.2211
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Staphylococcus aureus is a frequent cause of bac-
teremia, pneumonia, skin and soft tissue infection as
well as osteomyelitis and septic arthritis. The remarkable
pathogenic potential of this microbe has been demon-
strated over the past decade, with the rapid spread of
highly virulent, drug (methicillin)-resistant S. aureus strains
(MRSA). The search for protective immunity against inva-
sive S. aureus disease has been a research goal since the
discovery of this microbe, however this pursuit has not
yet been successful and a staphylococcal vaccine is cur-
rently not available. To identify protective antigens for a
staphylococcal vaccine, three models systems for S. aureus
infections in mice were developed - pneumonia, lethal sep-
ticemia and persistent abscess model. Using a combination
of molecular genetic tools, the genetic requirements of the
pathogen for each of the three disease complexes were char-
acterized. Genes encoding secreted products that proved
to be necessary for the pathogenesis in any one of three
disease models were examined further, subjecting the puri-
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ed products to vaccine trials for protective immunity.
ene products that generated protection were also tested
or cross-protection in other disease models or examined
or speciﬁc animal or human immune responses follow-
ng infection. Taken together these studies revealed that
taphylococci elicit only moderate host immune responses
o infection owing to their expression of several differ-
nt immune-suppressive molecules, in particular adenosine
ynthase AdsA. a-hemolysin was the sole protective anti-
en for staphylococcal lung infection. Antibodies against
eme-iron scavenging factors provided protective immunity
gainst staphylococcal abscess formation, whereas combi-
ations of different antibodies generated protection against
ethal septicemia in mice. These studies therefore suggest
hat the generation of a successful vaccine against S. aureus
nfection requires a combination of different antigens, but
annot be accomplished by a single factor.
oi:10.1016/j.ijid.2010.02.2212
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RSA in Latin America: special considerations
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Until the year 2000, epidemiological surveillance in Latin
merica was conducted in only a few countries, includ-
ng Venezuela and Argentina. Since then, with the support
f the Pan American Health Organization (PAHO), a net-
ork for surveillance of bacterial resistance has been
rganized, which includes the majority of Latin American
ountries: the Monitoring/Surveillance Network for Resis-
ance to Antibiotics. Criteria for admission of surveillance
enters to the network include concepts of standardization,
uality control, supervision visits and regular data report-
ng. Results are published each year on the PAHO web site
www.paho.org) .The data are collected during the daily
ork of selected laboratories in the region, with strong sup-
ort from national and regional reference laboratories.
The Resistance Group of the Panamerican Infectious Dis-
ases Asociation, under the leadership of Dr. Jose Maria
asellas has kept surveillance on the incidence of MRSA and
pdated reports are published on the API journal.
The methodology used for deﬁnition of a given strain as
RSA is different in each country. Some countries work with
he Bauer and Kirby method using the oxacillin or cefoxitin
isks, and others use automated methods like VITEK 1 or 2
bioMérieux) and/or MicroScan (Dade Behring).
Conﬁrmation tests such as the methicillin screen plate
est are not widely used. The high cost of E-test strips does
ot permit their routine use in laboratories in the region,
nd rapid methods of mecA gene detection are not available
or the majority of laboratories. Molecular analysis of MRSA
trains is restricted to some centers in Brazil, Argentina,
hile, Mexico and Colombia. In cases of nosocomial out-
reaks, the identity of MRSA strains is usually assumed from
he phenotypic pattern of antibiotic resistance.Nosocomial, multidrug-resistant MRSA is a growing
roblem in Latin America. Information gathered by the
AHO-sponsored program on nosocomial infections demon-
trated that for the year 2004, MRSA prevalence was as
